Editorial Board
EDITOR-IN-CHIEF:
Current Positions and Research Interests
Dr Johnson works for the UK Health Protection Agency in London undertaking surveillance of antibiotic resistance. He also teaches on a number of academic courses on aspects of medical microbiology. He is currently Editor-in-Chief of the Journal of Antimicrobial Chemotherapy
Declaration of Interests
Dr Johnson has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies: including AstraZeneca, Janssen-Cilag and Novartis. He is a member of the Prescribing sub-group of the Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI).
SENIOR EDITORS
J. P. Donnelly (Nijmegan, The Netherlands)
Current Positions and Research Interests
Dr Donnelly works for the Department of Haematology of the Radboud University Nijmegen Medical Centre. His main interests are the management and diagnosis of infectious complications in haematological malignancies and stem cell transplantation and he has extensive experience in the design, conduct, analysis and reporting of clinical trials. He has been involved in the Journal of Antimicrobial Chemotherapy for many years.
Declaration of Interests
Dr Donnelly has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies: including Astellas, Gilead, Merck and Pfizer. He chairs both the Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer Infectious Diseases Group and the European Aspergillus PCR Initiative – a Working Group of the International Society of Human and Animal Mycology (ISHAM). He is also secretary to the ISHAM, and is a member of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
F. K. Gould (Newcastle upon Tyne, UK)
Current Positions and Research Interests
Professor Gould is a Consultant Microbiologist and has been in her present appointment since 1988, working for the NHS Hospital Trust, over two sites within a busy teaching hospital, she is also Regional Microbiologist, Health Protection Agency, with special interest in Healthcare Associated Diseases. Professor Gould has an interest in the diagnosis and treatment of lower respiratory tract infections, and the management of infection in patients with impaired renal function including the diagnosis and treatment of peritonitis in Continuous Ambulatory Peritoneal Dialysis. In addition she has worked closely with the adult and paediatric thoracic transplant programme and is a member of the Infection Council of the International Society of Heart and Lung Transplantation.
Declarations of Interests
Professor Gould has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies: such as AstraZeneca, Astellas, Pfizer and Forest Labs.
L. Leibovici (Petah-Tiqva, Israel)
Current Positions and Research Interests
Leonard Leibovici heads the Department of Medicine at Beilinson Hospital, Rabin Medical Centre, Petah-Tiqva and is the Head of the Medical School and Vice-Dean at the Sackler Faculty of Medicine, Tel-Aviv University, Israel. His main research interests are computerized decision support, antibiotic treatment and evidence-based medicine.
Declaration of Interests
L. Leibovici has not received any funding or honoraria from the industry in the last 10 years, and has no other conflict of interest to declare.
R. L. Murphy (Chicago, USA)
Current Positions and Research Interests
Dr. Rob Murphy is currently the John P. Phair Professor of Infectious Diseases at Northwestern University where he is also Director, Center for Global Health. He holds academic appointments as Visiting Professor of Immunology and Infectious Diseases at Harvard School of Public Health and Professeur Associé de Recherche at the Pierre et Marie Curie Université in Paris.
Dr. Murphy’s primary research interest is in viral infections. His research includes drug development of new antiretroviral drugs, anti-hepatitis agents, therapeutic vaccines, the complications of antiviral therapy and the scale up of therapy for AIDS, tuberculosis and malaria in sub-Saharan Africa. Dr. Murphy is the Principal Investigator for the National Institutes for Allergy and Infectious Diseases (NIAID) Adult AIDS Clinical Trials Group (ACTG) at Northwestern. Within the ACTG he holds leadership positions including membership on the Executive Committee, the governing body of the group, co-chair of the Data Management Committee and membership on the Hepatitis Transformative Science Group. He is a member of multiple medical societies and sits on the boards of several non-profit organizations including the Drucker Family Charitable Trust, the International AIDS Education Project, Objectif Recherche Vaccin SIDA and the Midwest AIDS Foundation, of which he is the founder. International activities and interests include being Principal Investigator for the National Institutes for Health/Fogarty International Center’s AIDS International Training and Research Program based in Nigeria and Mali and the Medical Education Partnership Initiative in Nigeria. He has co-authored more than 240 scientific publications.
Declaration of Interests
Consultant to Gilead Sciences, Merck Pharmaceuticals, Argos Therapeutics; he is a founder and shareholder of InnaVirVax and shareholder of Idenix Pharmaceuticals.
D. S. Reeves (Bristol, UK)
Current Positions and Research Interests
Professor David Reeves retired from the NHS in 1998. After qualifying in medicine, and following posts at the Westminster, Edgware and St Mary’s Hospitals, he was Consultant Medical Microbiologist and Control of Infection Officer of Southmead Hospital for 27 years. He is Honorary Professor of Medical Microbiology, University of Bristol.
His main research interests were the treatment of UTI, evaluating new antibiotics in clinical practice, the development and use of clinical assays of antibiotics, TDM (particularly aminoglycosides), and antibiotic pharmacokinetics. This resulted in some 220 original publications and 120 reviews and book chapters.
He has held a number of positions in the BSAC (founder Council member, Meetings Secretary, General Secretary), and was an Editor of JAC (1985-91), member and chairman of what is now the Editorial Advisory Board (74-96), and Editor-in-Chief (2000-6). He is an Honorary Life member of the BSAC and a former Garrod medallist.
Professor Reeves has edited many supplements for JAC and also a number of books, and still referees regularly for other journals. He recently published a chapter on aminoglycosides in a standard reference work.
Declaration of Interests
Professor Reeves currently has no involvement with industry, although he was a consultant to many companies in the past up to 2008.
S. Schwarz (Neustadt-Mariensee, Germany)
Current Positions and Research Interests
Prof. Dr. med. vet. Stefan Schwarz works in the Institute of Farm Animal Genetics of the Friedrich-Loeffler-Institut (= Federal Research Institute for Animal Health) in Neustadt-Mariensee, Germany. He heads a research group entitled ‘Molecular Microbiology and Antimicrobial Resistance’ and is involved in both surveillance of antimicrobial resistance and analysis of the molecular genetics of antimicrobial resistance. He also teaches various academic courses at the University of Veterinary Medicine Hannover.
Declaration of Interests
Prof. Schwarz has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies including Bayer Animal Health, Boehringer Ingelheim, Elanco Animal Health, Intervet, Pfizer Animal Health, and Schering-Plough. He is a member of the Veterinary Antimicrobial Susceptibility Testing (VAST) subcommittee of the Clinical and Laboratory Standards Institute (CLSI) and the chairman of the working group ‘Antimicrobial Resistance’ of the German Veterinary Medical Society.
EDITORIAL BOARD
J. Ainsa (Zaragoza, Spain)
Current Positions and Research Interests
Dr José Ainsa is a Lecturer on Microbiology at the University of Zaragoza, Spain. His current research interests are the molecular basis of drug resistance in bacteria, more specifically in Mycobacterium tuberculosis and other mycobacteria, and drug discovery of antimycobacterial agents. He is particularly interested on the characterisation of efflux pumps and their contribution to drug resistance (both to old drugs and novel drug-candidates) and other bacterial proceses.
Declaration of Interests
Research in Jose Ainsa laboratory is funded by national programmes (Spanish Ministry of Science and Innovation (MICINN), Networked Research Centre on Respiratory Diseases (CIBERES)) and the European Union 7th Framework Programme (MM4TB, More Medicines for Tuberculosis).
R. Anthony (Amsterdam, The Netherlands)
Current Positions and Research Interests
Dr Richard Anthony leads the tuberculosis research activities at the Royal Tropical Institute, Amsterdam the Netherlands. His current research interests include the rapid detection of infection and drug resistance/susceptibility in M. tuberculosis. A particular interest of our department is provision of infectious disease diagnostics in high burden settings.
Declaration of Interests
Research in our laboratory is funded by national programmes, the European Union, and FIND Genève. Additionally we also occasionally perform small research projects funded by commercial partners, for example Philips Research.
G. Biagini (Liverpool, UK)
P. G. Bray (Liverpool, UK)
Current Positions and Research Interests
Pat Bray was a Reader in Molecular Parasitology at the Liverpool School of Tropical Medicine until his retirement in 2010. He spent almost 30 years at the School, during which time he developed a strong research interest in anti-parasite chemotherapy and drug resistance. Dr Bray now runs a smallholding and also works as a musician but remains interested in antimicrobial drug resistance.
Declaration of Interests
Dr Bray received research funding from academia until his retirement in 2010 but has not received any funding from commercial sources in the last ten years.
P. Chandrasekar (Detroit, USA)
Current Positions and Research Interests
P. H. Chandrasekar serves as Professor of Medicine/Infectious Diseases and is Director of the Infectious Diseases Fellowship Program at Wayne State University, Detroit, Michigan, USA. He also serves as the Chief of the Infectious Diseases section at Karmanos Cancer Institute, Detroit, Michigan. His major interests include management and prevention of infections in cancer patients and stem cell transplant recipients.
Declaration of Interests
Dr Chandrasekar has received research support, honoraria for lectures and consultancy fees from a number of pharmaceutical companies including Astellas, Merck, Pfizer and Enzon.
G. Davies (Liverpool, UK)
Current Positions and Research Interests
Gerry Davies is Senior Lecturer and Honorary Consultant in Infectious Diseases at the University of Liverpool. He ran the TB programme at Hlabisa hospital, Kwazulu/Natal, South Africa from 1994-1998; he later obtained an MSc in Epidemiology from the London School of Hygiene and a PhD in Pharmacology from the University of Liverpool. In 2009, Dr Davies completed a Wellcome Trust Training Fellowship based at the Mahidol-Oxford Research Unit in Bangkok where he worked on clinical studies of anti-tuberculosis and influenza therapy. He is currently managing PKPDia, an international collaboration aiming to advance pharmacokinetic-pharmacodynamic analysis in TB, HIV and malaria and is tuberculosis editor for the Cochrane Infectious Diseases Group.
His current research interests include: pharmacokinetics; pharmacodynamics and mathematical modelling of anti-tuberculosis therapy; bacteriological and other biomarkers of treatment response; clinical trial methodology and systematic reviews.
Declaration of Interests
Dr Davies has received support funding for travel to talks and honoraria from US/UK public sector and academic institutions and from the Novartis Tropical Institute, Singapore.
V. I. Enne (London, UK)
Current Positions and Research Interests
Dr Enne works at the Blizard Institute of Cell and Molecular Science, at Queen Mary, University of London. She undertakes research into various aspects of antimicrobial resistance and her interests include: silencing of antibiotic resistance genes; fitness cost of resistance; persistence of resistance in the absence of selection; and molecular mechanisms of resistance. She also teaches on various undergraduate microbiology courses. She is a member of the Editorial Board of the Journal of Antimicrobial Chemotherapy.
Declaration of Interests
Dr Enne currently receives research funding from The Wellcome Trust and has previously received funding from DEFRA and BSAC. She has not received funding from commercial organisations of any kind.
H. J. Field (Cambridge, UK)
Current Positions and Research Interests
Dr Field is Reader in Comparative Virology, working at the Veterinary School, University of Cambridge. He is also a Fellow and Director of studies in Medical and Veterinary Sciences at Queens' College, Cambridge. His research focuses on herpesviruses and antiviral agents, especially nucleoside analogues and helicase-primase inhibitors. His publications include original papers and reviews on the effects of antivirals in laboratory infection models and the mechanisms of antiviral resistance.
Declaration of Interests
Dr Field has received research funding or honoraria for lectures or consultancy from academia and a number of pharmaceutical companies, most recently Novartis and AiCuris Co, Germany. He is also Editor-in-Chief for the journal Antiviral Chemistry and Chemotherapy and serves on the Pathology Council for the Royal Society of Medicine.
G. Guaraldi (Modena, Italy)
Current Positions and Research Interests
Giovanni Guaraldi is Assistant Professor of Infectious Diseases at the University of Modena and Reggio Emilia. His primary research interests are lipodystrophy and cardiometabolic complications in patients with HIV infection. Since 2002, he has been the leader of the Metabolic Clinic of Modena University, a multidisciplinary referral clinic where a 3000 HIV patient cohort is monitored for HIV-associated chronic disease. He is the physician in charge of the HIV solid organ transplant centre in Modena where 20 HIV patients have so far received liver or kidney transplants. He is panel member of EACS Guidelines on the Prevention and Management of Metabolic Diseases in HIV.
Declaration of Interests
Giovanni Guaraldi has received research funding or honoraria for lectures or consultancy from both academia and a number of pharmaceutical companies including: Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag and Merck.
A. Hill (Liverpool, UK)
Current Positions and Research Interests
Dr Andrew Hill is a Senior Visiting Research Fellow at Liverpool University. Dr Hill has a first degree from Oxford University and a PhD from the University of Amsterdam. His speciality is the design and analysis of HIV clinical trials. He is working on antiretroviral treatment for developing countries.
Declaration of Interests
Dr. Hill conducts consulting work for Tibotec/Janssen-Cilag, on clinical trials of darunavir and etravirine. He is also the trustee of a UK charity, ‘Living and Loving’ which provides support for children with HIV/AIDS in Thailand.
R. Hope (London, UK)
Current Positions and Research Interests
Dr Hope works for the UK Health Protection Agency (HPA) in London undertaking surveillance of antibiotic resistance and healthcare associated infection. He currently heads the section responsible for the mandatory surveillance of bacteraemia and Clostridium difficile infection in England. Prior to this Russell ran surveillance programmes for the HPA's Antibiotic Resistance Monitoring and Reference Laboratory. Interests are focused on the epidemiology of infections cause by antimicrobial resistant pathogens, artificial intelligence for improved clinical diagnostics and antibiotic resistance mechanisms within the Enterobacteriaceae.
Declaration of Interests
Dr Hope has received support for research projects and/or conference attendance from a number of companies including, Pfizer, Wyeth (now Pfizer), Johnson & Johnson, Novartis, and Smith and Nephew.
K. L. Hopkins (London, UK)
Current Positions and Research Interests
Dr Hopkins works for the UK Health Protection Agency in London. Her research interests focus on mechanisms of antimicrobial resistance in enteric pathogens, and development and application of DNA-based typing methods for epidemiological investigations.
Declaration of Interests
Dr. Hopkins has no conflicts of interest to declare.
M. Hornsey (London, UK)
Current Positions and Research Interests
Mike Hornsey is a Postdoctoral Researcher at the Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London. His research interests include: mechanisms of resistance to antibacterial agents of last resort; the development of novel therapeutic strategies for the treatment of infections caused by problematic, nosocomial bacterial pathogens; pathogenic mechanisms of Gram-negative bacteria; invertebrate models of bacterial infection. He is also involved in teaching both undergraduate and postgraduate students at Queen Mary.
Declaration of Interests
Dr Hornsey’s research has been supported by Wyeth (now Pfizer), Astellas Pharma and Basilea Pharmaceutica. He has also received sponsorship to attend conferences from Pfizer.
P. J. Jenks (Plymouth, UK)
Current Positions and Research Interests
Dr Peter Jenks is a Consultant Microbiologist and Director of Infection Prevention and Control at Plymouth Hospitals NHS Trust. His research interests are primarily surveillance and the control of healthcare-associated infections.
Declaration of Interests
Dr Jenks has received honoraria for consultancy from Baxter. He is a member of the Council of the Hospital Infection Society.
C. Kirkpatrick (Melbourne, Australia)
Current Positions and Research Interests
Professor Carl Kirkpatrick is Head of Department of Pharmacy Practice and Co-Director of the Centre for Medicine Use and Safety, Monash University, Australia. He received his PhD from the University of Otago (New Zealand) in the area of aminoglycoside pharmacokinetics/pharmacodynamics. Prior to being awarded his PhD, Carl worked as a clinical pharmacist in the area of intensive care and Clinical Pharmacology. Since completing his PhD, his research has focused around the PK/PD of anti-infective agents and other treatments in the critically ill, and the optimisation of dosing in obesity and the renally impaired. His research interests include quantitative clinical pharmacology/pharmacometrics for PK/PD modelling, mechanism-based modelling, clinical pharmacokinetics, therapeutic drug monitoring, and Bayesian Methods for the optimisation of anti-infectives therapy (and other drugs) in difficult patient groups, for example critically ill and cystic fibrosis.
Declaration of Interests
Carl has received no personal support from any industry sources. However, he is involved with collaborative pharmaceutical industry projects with Pfizer and CSL.
R. J. Koerner (Sunderland, UK)
Current Positions and Research Interests
Roland Koerner is a Consultant Microbiologist at Sunderland Royal Hospital. Together with his colleagues he is responsible for the provision of clinical microbiology and infection control services to City Hospitals Sunderland NHS Foundation Trust. He is also Clinical Senior Lecturer of Newcastle University. His specific clinical interests are diagnosis and management of infection in the critical care setting and optimising antimicrobial chemotherapy by applying PK PD parameters.
Declaration of Interests
Roland Koerner has received sponsorship to attend conferences from Bayer Pharmaceuticals. Some of his students received unconditional educational grants from Pfizer, Bayer and Novartis.
P. D. Lister (Omaha, USA)
Current Positions and Research Interests
Dr Lister is a Professor of Medical Microbiology and Immunology at Creighton University School of Medicine in Omaha, Nebraska. In addition to being an Editor for the Journal of Antimicrobial Chemotherapy, he also serves on the editorial boards of other microbiology and infectious disease journals.
Declaration of Interests
Dr Lister has received funding for research, consultancy, and lecture honoraria from national and academic agencies, as well as pharmaceutical companies. Pharmaceutical companies that have supported his research and/or lectures include Ortho-McNeil, Pfizer, Merck, Calixa, Wyeth-Ayerst Lederle, Bristol-Myer Squibb, and Bayer.
L. Maes (Antwerp, Belgium)
Current Positions and Research Interests
Louis Maes is a veterinarian and, since 2002, a Professor at the University of Antwerp, where he is also director of the Laboratory for Microbiology, Parasitology and Hygiene (http://www.ua.ac.be/lmph). He was previously at the Johnson & Johnson divisions of Janssen Pharmaceutica (Beerse, Belgium) and Tibotec (Mechelen Belgium). His current research interests are antimicrobial drug discovery with particular emphasis on antiparasitics and antimycotics.
Declaration of Interests
Louis Maes currently receives funding for drug screening and evaluation from the World Health Organisation (WHO-TDR) and the Drugs for Neglected Diseases Initiatives (DNDi), and has ad hoc collaborations with pharmaceutical industry partners on a fee-for-service basis (Janssen Pharmacuetica, Barrier Therapeutics). He is currently member of the Belgian Federal Agency for Veterinary Medicines.
J.-Y. Maillard (Cardiff, UK)
Current Positions and Research Interests
Jean-Yves Maillard is a Reader in Pharmaceutical Microbiology at the Welsh School of Pharmacy at Cardiff University. His field of expertise concerns biocides; their activity, mechanisms of action and the emergence of microbial resistance and cross-resistance to antimicrobials. He is also working as a consultant for the biocidal industry, through Cardiff University, on matters related to microbicides.
Declaration of Interests
Jean-Yves Maillard's research has mainly been funded by industry and has led to the publication of > 90 articles and 11 book chapters and 1 book, all on biocides.
V. Mallet (Paris, France)
Current Positions and Research Interests
Vincent Mallet is an Assistant Professor of Hepatology in the Hepatology Unit of Cochin Saint-Vincent de Paul University Hospital, in Paris. Dr Mallet's clinical interests include liver regeneration, regression of cirrhosis and liver disease in HIV-infected and in immunocompromised patients. Dr Mallet is an active member of the French and European associations for the study of the liver and has been recognized as 'rising star in Hepatology' at the United European Gastroenterology Week that was held in Paris in 2007.
Declaration of Interests
Vincent Mallet has received honoraria for lectures, conference attendance, or consultancy from pharmaceutical companies including BMS, Gilead Science, Schering-Plough and Merck.
J. Meletiadis (Athens, Greece)
Current Positions and Research Interests
Dr. Joseph Meletiadis is a Ph.D. mycologist, Lecturer in Mycology at the Medical School of University of Athens and leader of Mycology Unit at the Clinical Microbiology Laboratory of Attikon University General Hospital of Athens, Greece. His main research interests are fungal infections model, molecular diagnostics and identification, antifungal susceptibility testing, pharmacokinetics and pharmacodynamics of antifungal drugs, in vitro and in vivo drug combinations.
Declaration of Interests
Dr. Joseph Meletiadis has received research funding or honoraria for lectures, conference attendance or consultancy from academia and pharmaceutical companies.
L. Ostrosky-Zeichner (Houston, USA)
Current Positions and Research Interests
Dr Ostrosky-Zeichner is currently an associate professor of medicine and epidemiology, associate fellowship program director, and director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the University of Texas Medical School at Houston. He also serves as medical director for epidemiology for Memorial Hermann Texas Medical Center. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America.
Declaration of Interests
Dr Ostrosky-Zeichner has received grant support and speaks and/or consults for Merck, Pfizer, Astellas, Viracor, GSK, Novadigm, and Gilead and has received grant support from Basilea and Associates of Cape Cod.
T. Parkinson (Sandwich, UK)
Current Positions and Research Interests
Tanya Parkinson is a biologist at Pfizer Global Research and Development, Sandwich Laboratories, Kent. She is responsible for leading drug discovery projects on infectious diseases, currently focusing on neglected tropical diseases such as malaria and Chagas disease. In the past she has also worked on drug discovery for HIV, hepatitis C and fungal infections.
Declaration of Interests
Tanya Parkinson owns shares in Pfizer Ltd.
J. D. Perry (Newcastle upon Tyne, UK)
Current Positions and Research Interests
Dr John Perry is a Clinical Microbiologist employed at the Freeman Hospital in Newcastle upon Tyne, UK. He is an Honorary Senior Lecturer at Newcastle University and a Visiting Professor at Northumbria University. He is a member of two BSAC Working Parties: one on susceptibility testing and the other on management of endocarditis. His research interests include diagnostic bacteriology and particularly the design of novel culture media.
Declaration of Interests
He has received funding for Research or Consultancy from diagnostics companies including bioMérieux, Becton Dickinson and Lab M
M. Peters (San Francisco, USA)
Current Positions and Research Interests
Dr Peters is a Professor of Medicine and Chief of Hepatology Research at the University of California at San Francisco, where she holds the John V. Carbone, MD, Endowed Chair in Medicine. Her research focuses on viral hepatitis in complicated clinical settings, including patients with HIV infection.
She leads the NIH AIDS Clinical Trial Group, studying therapy of HIV/HBV and HIV/HCV co-infections, and the Women¹s Interagency HIV study Hepatitis Working group.
Declaration of Interests
In 2011 I have consulted for Merck and Biotron. I am on scientific advisory boards for clinical care options and HEPDART. My husband works for Grad, a subsidiary of Roche.
L. Poirel (Paris, France)
Current Positions and Research Interests
Dr Laurent Poirel is a Senior Researcher of the INSERM (National Institute of Health and Medical Research) working in the Department of Microbiology at the Bicêtre hospital, South-Paris Medical School, France. He also an Associate Researcher at the Veterinary School of Maisons-Alfort, suburb of Paris. His research interests include emerging mechanisms of resistance to β-lactams and quinolones in Gram-negative rods. He specializes in the genetics of acquisition of broad-spectrum β-lactamases in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii, and plasmid-mediated quinolone resistance determinants in Enterobacteriaceae. He is the author of more than 280 publications in international journals and member of several journal editorial boards.
Declaration of Interests
He has occasionally received research funding or honoraria from pharmaceutical companies
S. Pournaras (Larissa, Greece)
Current Positions and Research Interests
Spyros Pournaras is medical microbiologist. He currently serves as Assistant Professor of Microbiology at the Medical School of University of Thessaly, Greece and also has clinical duties at the University Hospital of Larissa. His research interests are primarily antibiotic resistance mechanisms and molecular epidemiology of multidrug-resistant pathogens.
Declaration of Interests
Spyros Pournaras has not received funding or honoraria from commercial organisations.
V. Ricci (Birmingham, UK)
Current Positions and Research Interests
Dr Vito Ricci is a Senior Research Fellow at the University of Birmingham. His research interests are in various aspects of antimicrobial resistance especially the molecular mechanisms and regulation of multiple drug resistance in Salmonella enterica. He is a member of the Editorial Board of the Journal of Antimicrobial Chemotherapy.
Declaration of Interests
Dr. Ricci has no conflicts of interest to declare.
K.K. Scarsi (Chicago, USA)
Current Positions and Research Interests
Dr Kim Scarsi is a Research Assistant Professor in the Division of Infectious Diseases and Center for Global Health at the Northwestern University Feinberg School of Medicine in Chicago, IL, USA. She received her Doctor of Pharmacy degree from Drake University, completed post-graduate residency training at Northwestern Memorial Hospital, received her Master of Science in Clinical Investigation from Northwestern University, and is a Board Certified Pharmacotherapy Specialist with added qualifications in Infectious Diseases. Her research interests include the pharmacology of antiretroviral agents and medications commonly used to treat co-infections with HIV, pharmacologic considerations related to gender and pregnancy, management of HIV-related drug interactions, and evaluation of outcomes related to HIV care and treatment. Dr Scarsi is also active in capacity building and research mentorship in low- and middle-income countries through the President's Emergency Plan for AIDS Relief (PEPFAR) and AIDS International Training and Research Program (AITRP).
Declaration of Interests
Dr Scarsi serves as an author for Medscape Ask the Experts. She has not received honoraria or research support from industry sources. Her current grant support is through the National Institutes of Health, NIAID and the Fogarty International Center.
M.J. Schwaber (Tel Aviv, Israel)
Current Positions and Research Interests
Dr Schwaber is the Director of the National Center for Infection Control of the Israel Ministry of Health.
He is also an attending physician in the Department of Consultative Medicine at the Tel Aviv Sourasky Medical Center, and a consultant in infectious diseases for Maccabi Healthcare Services.
Dr Schwaber’s research interests include the molecular epidemiology of healthcare-associated, antimicrobial-resistant bacteria.
Declaration of Interests
None to declare
E. Tacconelli (Rome, Italy)
Current Positions and Research Interests
Dr Tacconelli is an Assistant Professor of Infectious Diseases at Università Cattolica Sacro Cuore in Rome, Italy. In addition to being an Editor for the Journal of Antimicrobial Chemotherapy, she also serves on the editorial boards of other infectious disease journals. Her specific research interests include infection control, epidemiology and clinical aspects of healthcare-associated infections due to antimicrobial-resistant bacteria.
Declaration of Interests
Dr Tacconelli has received funding for research, consultancy, and lecture honoraria from national and academic agencies, as well as pharmaceutical companies. Pharmaceutical companies that have supported her research and/or lectures include Astellas, Novartis, Pfizer, Sanofi-Aventis, and Merck.
B. Taiwo (Chicago, USA)
Current Positions and Research Interests
Dr Babafemi Taiwo is an Infectious Diseases Physician, Teacher and Researcher at the Feinberg School of Medicine, Northwestern University. He is also affiliated with Northwestern University's Center for Global Health. His research interests include optimization of antiretroviral therapy, antiretroviral drug resistance and international health.
Declaration of Interests
Dr Babafemi Taiwo has served as an advisor and/or received research support (to Northwestern University) and honoraria from Janssen, GlaxoSmithKline and ViiV.
A. Thomson (Glasgow, UK)
Current Positions and Research Interests
Alison Thomson is a pharmacist with a joint clinical and research background. She currently has a part-time area pharmacy specialist post in clinical pharmacokinetics within NHS Greater Glasgow and Clyde and also works as a part-time senior lecturer within the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde. Alison previously ran a therapeutic drug monitoring laboratory at Stobhill Hospital in Glasgow. Her research interests are in the area of clinical pharmacokinetics and the use of pharmacokinetic modelling techniques to design drug dosage regimens for patient populations and for individual patients. She runs clinical pharmacokinetic training courses within the NHS and is occasionally invited to give lectures or workshops at scientific meetings or at meetings of other healthcare professionals.
Declaration of Interests
Dr Thomson has no conflicts of interest to report.
A. Tsakris (Athens, Greece)
Current Positions and Research Interests
Athanassios Tsakris graduated as an MD from the Medical School of University of Athens, Greece and completed his training in Medical Microbiology at North Middlesex Hospital, London and the Central Public Health Laboratory, London. He received his PhD degree from the London School of Hygiene and Tropical Diseases, University of London. He is a Fellow in Medical Microbiology and Virology at the Royal College of Pathologists, London.
Prof Tsakris is currently Professor and Head of the Department of Microbiology at the Medical School, University of Athens, Greece. He teaches various undergraduate and postgraduate academic courses at the University of Athens. His major interests include surveillance of multidrug-resistant pathogens and molecular mechanisms of antimicrobial resistance. In addition to being an Editor for the Journal of Antimicrobial Chemotherapy, he also serves on the editorial boards of other microbiology/infectious disease journals.
Declaration of Interests
Prof Tsakris has occasionally received research funding from both academia and pharmaceutical companies.
A.J. Ullmann (Würzburg, Germany)
Current Positions and Research Interests
Andrew J. Ullmann serves as Professor of Medicine/Infectious Diseases and is Head of Infectious Diseases at Julius-Maximilians University, Wuerzburg, Germany. He is a fellow of the Infectious Diseases Society of America. His major interests include the development of new antimicrobial agents, the management and prevention of infections in immunosuppressed patients especially patients with haematological malignancies and haematopoietic stem cell transplant recipients.
Declaration of Interests
Andrew Ullmann has received research support, honoraria for lectures and consultancy fees from a number of pharmaceutical companies including Astellas, Basilea, Gilead, Merck (MSD and former Schering-Plough), and Pfizer.
E. van Duijkeren (Utrecht, The Netherlands)
Current Positions and Research Interests
Dr Engeline van Duijkeren works at the Laboratory for Zoonoses and Environmental Microbiology at the National Institute for Public Health and the Environment (RIVM) in Bilthoven, The Netherlands. Her research interests focus on the epidemiology and mechanisms of antimicrobial resistance in staphylococci and Enterobacteriaceae including transmission of zoonotic bacteria between animals and humans.
Declaration of Interests
Reasearch at our laboratory is mainly funded by the government and national programmes. Dr van Duijkeren currently has no involvement with industry, but in the past she received research support and consultancy fees from pharmaceutical industry including Pfizer and Intervet/MSD Animal Health. I am a member of the editorial board of Veterinary Microbiology. She is also a member of the Scientific Advisory Group on Antimicrobials (SAGAM) of the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA).
P. Wade (London, UK)
G. Werner (Wernigerode, Germany)
Current Positions and Research Interests
Guido Werner works as a Medical Microbiologist in the Unit ‘Nosocomial Infections’ at the Department of Infectious Diseases, Robert Koch-Institute, Wernigerode Branch, Germany and is the Head of the National Reference for Staphylococci and Enterococci. He is also an Associate Professor for Medical Microbiology and gives lectures on this subject at the Georg-August-University Goettingen and the Technical University Brunswick. His main research interests are in methods of rapid and molecular diagnostics, molecular strain characterization/typing and population analysis of bacterial pathogens and all biological and epidemiological aspects of antimicrobial resistance. Dr Werner has worked for 18 months as a national expert at the European Commission, General Directorate ‘Health and Consumer Protection’ in the Unit ‘Health threats’ (DG SANCO C3) and is the nominated ‘National Microbiology Focal Point’ of a microbiological working group at the European CDC, Stockholm, Sweden.
Declaration of Interests
None to declare
H. Wickens (London, UK)
Current Positions and Research Interests
Dr Hayley Wickens is a microbiology specialist pharmacist with a background in both clinical practice and research. She is an Honorary Lecturer in the Department of Medicine, Imperial College London and Honorary ID research pharmacist, Imperial College Healthcare NHS Trust. Her research and teaching interests include antibiotic stewardship, pharmaceutical microbiology and monitoring of antibiotic consumption. Hayley also works for the British Society for Antimicrobial Chemotherapy as the UK data co-ordinator for the European Surveillance of Antimicrobial Chemotherapy project.
Declaration of Interests
Hayley Wickens has received funding or honoraria for lectures, conference attendance or consultancy from academia and a number of pharmaceutical companies including AstraZeneca, Novartis, Wyeth and GSK.
A. Zolopa (Palo Alto, USA)
Current Positions and Research Interests
Professor of Medicine, Stanford University School of Medicine.
The patient-oriented research program Dr Zolopa has developed since joining the faculty at Stanford University in 1994 ranges from clinical cohort studies to clinical trials - all aimed at optimizing antiretroviral therapy for HIV-infected adults. Since 2003, he has been the Principal Investigator for the Stanford AIDS Clinical Trials Unit. He Chaired the ACTG clinical trial (A5164) that demonstrated early ART in the setting of acute AIDS-related Opportunistic Infections resulted in reduced AIDS-morbidity and mortality. He is currently developing “The Stanford HIV Aging Group” (“SHAG”) - a cohort to study the immunologic basis of ‘premature’ aging in HIV infected adults. He is also leading a Stanford/Rwanda Mentoring program focusing on growing the HIV clinical research capacity in Rwanda, Africa.
Declaration of Interests
Dr Zolopa has received honoraria or funding for lectures, conference attendance, research, and/or consultancy from a number of pharmaceutical companies: Abbott Laboratories, Gilead Sciences, Pfizer, Bristol-Meyers Squibb, VIRxSys, Glaxo Smith Kline, and Janssen.
STATISTICAL ADVISER:
A. J. Hedges (Bristol, UK)
Current Positions and Research Interests
Alan Hedges was Senior Lecturer in Bacteriology in the University of Bristol until his retirement, when he was appointed honorary Research Fellow in the School of Cellular & Molecular Medicine.
His research interests are centred on the development of statistical methods and their application to microbiological problems.
Declaration of Interests
None to declare.
EPIDEMIOLOGICAL ADVISERS
A. Fraser (Bristol, UK)
Current Positions and Research Interests
MRC Research Fellow at the MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol. Dr Fraser was awarded her PhD
(Epidemiology) from the University of Bristol in 2008. Her research interests include lifecourse epidemiology of insulin resistance and cardiovascular disease; women's reproductive health; and evidence synthesis.
Declaration of Interests
None to declare.
T. Lamagni (London, UK)
Current Positions and Research Interests
Theresa Lamagni graduated in Psychology (BSc) in 1994 and came to work for the Public Health Laboratory Service (now Health Protection Agency) Communicable Disease Surveillance Centre in 1995 as a research assistant within the HIV & STI Department. During this time she completed an MSc in Epidemiology at the London School of Hygiene & Tropical Medicine. In May 2001, she joined the newly formed Healthcare Associated Infection & Antimicrobial Resistance Department within the HPA in London as a senior epidemiologist. She completed her PhD on the epidemiology of severe group A streptococcal infections in Europe at the University of Helsinki in 2008. She currently manages the surgical site infection surveillance programme and is involved in a number of national and international projects concerned with developing new surveillance initiatives, research programmes and public health policies.
Declaration of Interests
Theresa Lamagni has no conflicts of interest to declare.
EDITORIAL MANAGER
C. W. E. Drummond
Colin has a BSc in Microbiology and Virology from the University of Warwick and an MSc from the University of Oxford. He started his scientific publishing career at the Society for General Microbiology in 1992 as a Staff Editor for the Journal of General Virology. In 1996 he moved to International Medical Press in London, working on the titles International Antiviral News, Antiviral Chemistry and Chemotherapy and Antiviral Therapy. Colin joined JAC as Editorial Manager in 1999.
SENIOR STAFF EDITOR
C. L. Jeeves
Dr Clare Jeeves is the Senior Staff Editor for JAC. She has a first class honours degree in Molecular Cell Biology from the University of Nottingham (1993-1996) and a PhD in Biochemistry from the University of Birmingham (1996-1999). On completion of her PhD Clare decided to move from research into publishing and spent 2.5 years working for Portland Press in London (working mainly on the Biochemical Journal) before joining JAC in March 2002.
STAFF EDITOR
S. Brockhouse
Suzanne has a BSc in Applied Biology from the University of Bath and a PhD in Behavioural Chemical Ecology from the University of Southampton. After completing her PhD, Suzanne worked for the Society for Experimental Biology on their publication ventures before joining the Company of Biologists Ltd in 2008 where she worked as a Production Editor for The Journal of Experimental Biology. Suzanne joined the JAC Editorial team in September 2010 as a Staff Editor.
Publishers: Sending books for review
